Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Case
-
Reference no. 9-821-076
Subject category: Entrepreneurship
Published by: Harvard Business Publishing
Originally published in: 2021
Version: 9 June 2021
Length: 9 pages
Data source: Published sources

Abstract

uBiome provided clinical tests that sequenced the DNA of human microbiome samples, providing data on health conditions directly to consumers or to prescribing physicians. Founded in 2012, the San Francisco-based startup raised USD105 million from top-tier venture capital firms and recruited prominent biotech executives and scientists as board members and advisors. In April 2019, the FBI raided uBiome's offices to investigate claims that the company had repeatedly billed individuals without their consent to meet aggressive revenue targets. uBiome's cofounders/co-CEOs resigned soon afterward. The company declared bankruptcy later that year after a board committee concluded that management had indeed pursued policies of questionable legality, including improper insurance billing practices, improper use of a telemedicine physician network, overly aggressive marketing tactics, and the presentation of misleading information in fundraising pitches.

About

Abstract

uBiome provided clinical tests that sequenced the DNA of human microbiome samples, providing data on health conditions directly to consumers or to prescribing physicians. Founded in 2012, the San Francisco-based startup raised USD105 million from top-tier venture capital firms and recruited prominent biotech executives and scientists as board members and advisors. In April 2019, the FBI raided uBiome's offices to investigate claims that the company had repeatedly billed individuals without their consent to meet aggressive revenue targets. uBiome's cofounders/co-CEOs resigned soon afterward. The company declared bankruptcy later that year after a board committee concluded that management had indeed pursued policies of questionable legality, including improper insurance billing practices, improper use of a telemedicine physician network, overly aggressive marketing tactics, and the presentation of misleading information in fundraising pitches.

Related